Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$0.84 - $1.22 $1,940 - $2,818
-2,310 Reduced 12.61%
16,007 $19,000
Q3 2023

Nov 09, 2023

BUY
$0.82 - $1.42 $2,342 - $4,056
2,857 Added 18.48%
18,317 $15,000
Q2 2023

Aug 08, 2023

BUY
$1.09 - $9.93 $16,851 - $153,517
15,460 New
15,460 $18,000
Q2 2022

Aug 11, 2022

SELL
$2.21 - $5.56 $25,014 - $62,933
-11,319 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$5.07 - $13.68 $3,675 - $9,918
725 Added 6.84%
11,319 $57,000
Q4 2021

Feb 10, 2022

BUY
$11.91 - $17.0 $126,174 - $180,098
10,594 New
10,594 $136,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.